Judith Gail Deal

US Patent:

6495699, Dec 17, 2002

Filed:

Aug 6, 2001

Appl. No.:

09/922206

Inventors:

Steven L. Bender - Oceanside CA
Arlindo L. Castelhano - New City NY
Wesley K. M. Chong - Encinitas CA
Melwyn A. Abreo - Imperial Beach CA
Roland J. Billedeau - Santa Clara CA
Jian Jeffrey Chen - Santa Clara CA
Judith G. Deal - Temecula CA

Assignee:

Agouron Pharmaceuticals Inc. - La Jolla CA

International Classification:

C07D23354

US Classification:

5483361, 548215, 5483381, 5483751, 540524

Abstract:

The present invention is directed to compound of the formula I: wherein R , R , R , R , R , X, Y, and are as defined herein. These compounds are useful for inhibiting the activity of a metalloproteinase by contacting the metalloproteinase with an effective amount of the inventive compounds.

US Patent:

6635641, Oct 21, 2003

Filed:

Jan 19, 2001

Appl. No.:

09/764306

Inventors:

Steven Lee Bender - Oceanside CA
Dilip Bhumralkar - San Diego CA
Michael Raymond Collins - San Diego CA
Stephen James Cripps - San Diego CA
Judith Gail Deal - Wildomar CA
Lei Jia - San Diego CA
Mitchell David Nambu - San Diego CA
Cynthia Louise Palmer - La Mesa CA
Zhengwei Peng - San Diego CA
Michael David Varney - Solana Beach CA

Assignee:

Agouron Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07D24118

US Classification:

514247, 544224, 544238, 544408, 544410, 544236, 544237, 544353, 544354, 51425201, 514248, 51425505, 5142521, 5482632, 5483661, 548375, 546139, 546141, 546153, 546181, 546329, 546339, 546345, 546118, 546119

Abstract:

Amide compounds represented by the formula: wherein: R is a moiety represented by the formula âwhere X is selected from the group consisting of CH , O, S, and NH; and Y is selected from the group consisting of CH , O, and S, provided that at least one of X and Y is CH , or X and Y together with the bond there-between form a cyclopropyl; are described. These compounds and pharmaceutical compositions containing them modulate and/or inhibit the activity of certain protein kinases and are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

US Patent:

6869962, Mar 22, 2005

Filed:

Jun 11, 2003

Appl. No.:

10/460010

Inventors:

Michael Collins - San Diego CA, US
Stephan Cripps - San Diego CA, US
Judith Deal - Wildomar CA, US
Robert Steven Kania - San Diego CA, US
Jihong Lou - San Diego CA, US
Mingying He - San Diego CA, US
Cynthia Louise Palmer - La Mesa CA, US
Ru Zhou - Carlsbad CA, US

Assignee:

Agouron Pharmaceuticals, Inc. - La Jolla CA

International Classification:

A61K031/4365
C07D495/04
C07D409/14

US Classification:

514301, 546114

Abstract:

The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, Rand R, R, R, and Rare as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.

US Patent:

7045528, May 16, 2006

Filed:

Mar 9, 2004

Appl. No.:

10/796226

Inventors:

Michael Collins - San Diego CA, US
Stephan Cripps - San Diego CA, US
Judith Deal - Wildomar CA, US
Robert Steven Kania - San Diego CA, US
Jihong Lou - San Diego CA, US
Mingying He - San Diego CA, US
Cynthia Louise Palmer - La Mesa CA, US
Ru Zhou - Carlsbad CA, US

Assignee:

Agouron Pharmaceuticals, Inc. - La Jolla CA

International Classification:

A61K 31/4365
C07D 495/04

US Classification:

514301, 546114, 544127, 544180, 544331, 544336, 544362, 5142338, 514241, 514253, 514275

Abstract:

The invention relates to compounds represented by the formula I.

US Patent:

7772246, Aug 10, 2010

Filed:

Jul 30, 2008

Appl. No.:

12/182977

Inventors:

Jingrong Jean Cui - San Diego CA, US
Judith Gail Deal - Wildomar CA, US
Danlin Gu - San Diego CA, US
Chuangxing Guo - San Diego CA, US
Mary Catherine Johnson - San Diego CA, US
Robert Steven Kania - San Diego CA, US
Susan Elizabeth Kephart - San Diego CA, US
Maria Angelica Linton - San Diego CA, US
Indrawan James McAlpine - San Diego CA, US
Mason Alan Pairish - San Diego CA, US
Cynthia Louise Palmer - La Mesa CA, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61K 31/505

US Classification:

514275, 544331, 546113, 5483731

Abstract:

The present invention is directed to compounds of Formula (I),.

US Patent:

20040092747, May 13, 2004

Filed:

Jul 17, 2003

Appl. No.:

10/621979

Inventors:

Steven Bender - Oceanside CA, US
Michael Collins - San Diego CA, US
Stephen Cripps - San Diego CA, US
Judith Deal - Wildomar CA, US
Lei Jia - San Diego CA, US
Mitchell Nambu - San Diego CA, US
Cynthia Palmer - La Mesa CA, US
Zhengwei Peng - San Diego CA, US
Michael Varney - Solana Beach CA, US

International Classification:

C07D271/12
C07D285/14
C07D249/08

US Classification:

548/131000, 548/136000, 548/262200

Abstract:

Amide compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction in order to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

US Patent:

20050090529, Apr 28, 2005

Filed:

Aug 2, 2004

Appl. No.:

10/910217

Inventors:

Indrawan McAlpine - San Diego CA, US
Judith Deal - Wildomar CA, US
Mary Johnson - San Diego CA, US
Susan Kephart - San Diego CA, US
Julie Park - Cambridge MA, US
William Romines - San Diego CA, US
Jayashree Tikhe - San Diego CA, US

International Classification:

A61K031/4439
C07D043/14

US Classification:

514338000, 546268100

Abstract:

3,5 disubstituted indazole compounds with substituted nitrogen bearing 5-membered heterocycles in the 3-position that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

US Patent:

20060079548, Apr 13, 2006

Filed:

Oct 21, 2005

Appl. No.:

11/256477

Inventors:

Michael Collins - San Diego CA, US
Stephan Cripps - San Diego CA, US
Judith Deal - Wildomar CA, US
Robert Kania - San Diego CA, US
Jihong Lou - San Diego CA, US
Mingying He - San Diego CA, US
Cynthia Palmer - La Mesa CA, US
William Romines - San Diego CA, US
Ru Zhou - Carlsbad CA, US

International Classification:

A61K 31/4743
C07D 498/02

US Classification:

514301000, 546114000

Abstract:

The invention relates to compounds represented by the formula I and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, Rand R, R, R, and Rare as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.